10,221 Shares in CME Group Inc. (NASDAQ:CME) Bought by Insight Inv LLC

Insight Inv LLC bought a new stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,221 shares of the financial services provider's stock, valued at approximately $2,712,000. CME Group makes up approximately 1.0% of Insight Inv LLC's holdings, making the stock its 29th largest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC boosted its position in CME Group by 612.5% during the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock worth $30,000 after purchasing an additional 98 shares during the period. Alpine Bank Wealth Management acquired a new stake in CME Group in the 1st quarter valued at approximately $32,000. New Age Alpha Advisors LLC increased its position in CME Group by 50.0% in the 4th quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after buying an additional 43 shares during the period. Knuff & Co LLC acquired a new position in shares of CME Group during the fourth quarter worth approximately $33,000. Finally, Banque Transatlantique SA bought a new stake in shares of CME Group in the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 87.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on CME. Morgan Stanley upped their price objective on shares of CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. JPMorgan Chase & Co. cut their price target on shares of CME Group from $223.00 to $211.00 and set an "underweight" rating for the company in a research note on Thursday, April 24th. Bank of America upped their price objective on CME Group from $200.00 to $219.00 and gave the company an "underperform" rating in a research note on Wednesday, April 2nd. Oppenheimer increased their target price on CME Group from $282.00 to $300.00 and gave the stock an "outperform" rating in a report on Wednesday, June 4th. Finally, UBS Group boosted their price target on CME Group from $290.00 to $305.00 and gave the company a "buy" rating in a research note on Friday, April 25th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $258.20.

CME Group Stock Up 0.7%

Shares of NASDAQ:CME opened at $274.76 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.13. The firm has a market cap of $99.01 billion, a P/E ratio of 27.64, a P/E/G ratio of 3.73 and a beta of 0.45. CME Group Inc. has a 12 month low of $193.17 and a 12 month high of $290.79. The company's 50-day moving average price is $275.21 and its two-hundred day moving average price is $256.83.

CME Group (NASDAQ:CME - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. The company had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. CME Group had a net margin of 57.71% and a return on equity of 14.03%. CME Group's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.50 earnings per share. As a group, research analysts forecast that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were given a $1.25 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a yield of 1.82%. CME Group's payout ratio is 50.30%.

Insider Activity

In other CME Group news, Director William R. Shepard bought 256 shares of CME Group stock in a transaction dated Wednesday, June 25th. The shares were bought at an average price of $270.53 per share, with a total value of $69,255.68. Following the purchase, the director now owns 258,196 shares of the company's stock, valued at $69,849,763.88. This trade represents a 0.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Larry G. Gerdes sold 2,000 shares of CME Group stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $264.10, for a total transaction of $528,200.00. Following the sale, the director now directly owns 38,651 shares of the company's stock, valued at $10,207,729.10. This represents a 4.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,400 shares of company stock valued at $3,680,610. Company insiders own 0.30% of the company's stock.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.